Peptide Library

Human study PLS-00038

Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction.

Case-control study · 80 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction.primary · Scientific reports · 2026-02-12 · PMID 41680431 · DOI · corrected

Design and participants

Design
Case-control study
Population
Women with polycystic ovary syndrome and age- and BMI-matched healthy control women
Conditions
Polycystic ovary syndrome
Planned enrollment (registry)
Not reported
Enrolled
80
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no intervention was given and no safety monitoring was reported

    The authors concluded (paraphrased): Women with PCOS have reduced MOTS-c in both serum and skeletal muscle. This is linked to hyperandrogenism and lipid profile, suggesting that MOTS-c may be a marker of tissue-specific mitochondrial involvement in PCOS that merits further study.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: The study measures endogenous MOTS-c levels only; no MOTS-c was administered, so it gives no evidence on effects or safety of the compound.
    • confounding: Observational case-control comparison matched only on age and BMI; other differences between groups may explain the findings.
    • small or imprecise: Only 40 women per group, a muscle-biopsy subgroup of unstated size, and weak correlations near p=0.05.
    • abstract only: Only the abstract is available in the record, so methods, subgroup size, funding and conflicts cannot be checked.
    • inappropriate population: Women with PCOS do not match the claim population of adults with obesity, insulin resistance or type 2 diabetes treated with MOTS-c.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 41680431, abstract (sentence 5) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 41680431, abstract (sentences 11-13) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 41680431, abstract (sentences 5-7) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 41680431, abstract (sentences 5-10) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 41680431, abstract (sentences 6-7) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 41680431, abstract (sentence 5) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 41680431, abstract (sentence 5) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 41680431, abstract (sentences 8-10) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).